Joshua Parker retweeted
Received this email from the Journal of Marketing & Supply Chain Management (ISSN: 2754-6683).
One of the formats you can submit is a Powerpoint presentation.
This made me wonder, has anybody published a powerpoint presentation in a journal which is considered both high quality and legitimate?
... and has that powerpoint "publication" been cited?
Let me know.
===
Journal URL: buff.ly/y1NTd6U (archived at buff.ly/O4eLyRd)
Publisher (Scientific Research and Community): buff.ly/3yfGmq6 (archived at buff.ly/m6NvY9e)
Joshua Parker retweeted
Deaths: Leading Causes for 2024
National VitalStatistics Reports
Volume 75, Number 7 September 22, 2026
cdc.gov/nchs/data/nvsr/nvsr7…
Joshua Parker retweeted
Medical debt remains a challenge even for people with private health insurance.
The findings highlight how out-of-pocket costs can create financial pressure and reinforce the need for greater transparency and affordability in healthcare.
A survey of 4,000+ U.S. adults, all with private health insurance, found that nearly a third are paying off medical debt, according to @MedEconomics. Nearly half of the respondents with medical debt owe $2,000 or more: medicaleconomics.com/view/me…
Joshua Parker retweeted
We’re breaking ground in Houston, TX — the latest manufacturing site as part of our $50+ billion investment in domestic production. Not only will this new facility create hundreds of jobs, but it will help us get our medicines to people faster. go.lilly.com/hf3loa
#WeAreLilly
Joshua Parker retweeted
New research from ECOG-ACRIN and Caris Life Sciences, now available online in "npj Breast Cancer," supports the broader scientific rationale underlying Caris MI Clarity™ and highlights the potential of multimodal AI to advance distant recurrence-risk assessment in HR+/HER2−, node-negative early breast cancer.
In the independent validation group, IICM+ significantly outperformed the 21-gene Recurrence Score in distinguishing between patients at different risks of recurrence.
Learn more: ow.ly/yCrV50ZQcW6
Under investor pressure, Novo presented its strategy to both grow its obesity franchise and diversify its pipeline. trib.al/1Tq0AAK
Joshua Parker retweeted
This is crazy. It's right to retract - but it should NEVER have got through the editorial processes. How hard is it to check for things like this.
... I did hear another view (long time ago - can't remember who made the point) that in some ways it is good, as:
1⃣It highlights that the authors have acted frauduently - if it was just "rejected" nobody would know.
2⃣ They would have spent a lot of effort getting the paper "published" to no avail.
3⃣ They would have spent money on APCs, which have been wasted.
4⃣ If there were additional charges for the "paper mill" activity, those authors who are now out of pocket may demand their money back from the paper millers.
Not saying that @ElsevierConnect were thinking like this and not saying that it is a good way to deal with these type of papers (for one the authors can still list the paper as it is not always obvious that it is retracted), but I can see that there are some "benefits" to the points above.
#papermill #fraud at its best! All (!!) the authors of this paper were added during the revision process, replacing the 6 original authors! Unbelievable. @ElsevierConnect is rotten to the core! Thousands of such papers are being published.👇
doi.org/10.1016/j.envres.202…
Joshua Parker retweeted
📚 New #ICRJournal Article: "Five Practical Considerations for the Management of OHCA"
📚 Just Published!
🔓Access it here 👉 ow.ly/kP5y106F2o2
@ncurzen #MedEd #CardioEd
Joshua Parker retweeted
As you would expect this is total guff from Mad Ed.
Because the real agenda at the UN General assembly is focused on SDG progress, the UN itself describing this meeting as “decisive and the final stretch”
The UN has stated the goals aren’t being delivered quickly enough and implementation needs accelerating.
Money is the central theme with “how the UN is turning SDG priorities into investable capital” and Ai is being explicitly integrated into all of the SDGs
I’ll have a full non propaganda un guffed update for you later.
Joshua Parker retweeted
The Dramatic Rise of #GLP1 Prescribing in Heart Failure - @ConscienHealth conscienhealth.org/2026/09/2…
Joshua Parker retweeted
nitter.cf/haider1/status/2101368… An accelerationist perspective on this. Consider that the future is always uncertain, and that the future is rarely worse than the past. The enemy is not uncertainty, it is instability. Accelerate through it, back to stability, it is uncertain either way.
Joshua Parker retweeted
WATCH: Fit induction-eligible AML — aza-ven instead of 7+3/CPX? PARADIGM EFS 14.5 vs 6.2 mo 🩸
👉 oncologytube.com/paradigm-am…
🔹 Ph2 NEJM (Sep 2, 2026); N=172; HR 0.57 (95% CI 0.39–0.84; P=0.002)
🔹 Grade ≥3 infection 28% vs 41%; hemorrhage 2% vs 12%
🔹 Phase 2 only — not an FDA indication change; OS still maturing
EFS signal for fit adults — read the caveats before rewriting induction Monday morning.
@OncoAlert @NEJM @Dr_AmerZeidan @Daver_Leukemia @MikkaelSekeres @TapKadia @garciamanero @VJHemOnc @ASH_hematology @AML_Hub @AmyDeZern @jaltmanmd @TalhaBadarMD @sanamloghavi @GhayasIssa @MassGenBrigham @mtmdphd @Mohty_EBMT @BloodCancerJnl @oncodaily @CancerNetwrk @EuniceWangMD @UTMDAnderson @BloodPortfolio
#AML #PARADIGM #venetoclax #azacitidine #leusm #NEJM
Joshua Parker retweeted
When Wegovy tablets launched, many experts were skeptical, but the product's runaway success proved them wrong. New research by @JaimeAlmandoz and @BevTchangMD offers insight on what so many people missed.
conscienhealth.org/2026/09/2…
Joshua Parker retweeted
Out for a short holiday lads.
Let’s hope parasite Burnham blows everything up even more than he already has haha! 🚨
Joshua Parker retweeted
The Sunday Signal Podcast is live: Is AI going to take over?
@OpenAI's "rogue" agents, @AnthropicAI's 10%, Amodei's slowdown essay, @Oracle's 6am email.
Links below.
Joshua Parker retweeted
Very pleased to be in this beautiful Mayfair Resort, Raipur to speak at the BMC Cancer Conclave organized by my amazing friend @SirohiBhawna
Joshua Parker retweeted
The FDA approved Inluriyo plus Verzenio for certain patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In EMBER-3, the combination more than doubled median progression-free survival. #BreastCancer #FDAApproval
Joshua Parker retweeted
Enjoy this tweet? follow me @tangming2005 and join my newsletter to learn computational biology divingintogeneticsandgenomic…
Joshua Parker retweeted
One thing about me, I will definitely wound you with encouragement. Here, we don’t give up, we go again until we make it 💪
Joshua Parker retweeted
🧬 Longevity & Aging Series (S3, E7):
Dr. Amparo Santamaria discusses her #study on enhancing oocyte activation in women with ovarian failure using stem cell–based approaches.
🎥 youtube.com/watch?v=Zlezd0x_…
#author #interview #aging #oocyte #ovary #oa #publication #journal #meded